Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
This is a Phase Ib, open-label, multicenter study designed to assess the safety,
tolerability, and pharmacokinetics of coadministration of intravenous (IV) dosing of
atezolizumab (an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody) and oral
dosing of cobimetinib in participants with metastatic or locally advanced cancer for which no
standard therapy exists.